Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berg

Showing results (421-430 of 632) with videos related to

Pageof 64
Sort By:
Journal of Hepatology|July 23, 2008
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infectionJuliane Halangk, Christoph Sarrazin, Konrad Neumann, et al.
Journal of Virology|March 29, 2013
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patientsJulia Dietz, Sven-Eric Schelhorn, Daniel Fitting, et al.
Journal of Hepatology|April 2, 2017
Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral loadSandra Westhaus, Maximilian Deest, Anna T X Nguyen, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 23, 2019
The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieuHans Dieter Nischalke, Philipp Lutz, Eva Bartok, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2020
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort studyPietro Lampertico, Thomas Berg, Maria Buti, et al.
Cancers|October 14, 2022
Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular CarcinomasAnne Olbrich, Olga Gros, Sebastian Ebel, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Purinergic Signalling|September 24, 2018
Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent mannerStephanie Kuhn, Katrin Splith, Cindy Ballschuh, et al.
JHEP Reports : Innovation in Hepatology|September 25, 2023
HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriersLuisa Roade, Mar Riveiro-Barciela, Maria Pfefferkorn, et al.
Pageof 64

Showing results (421-430 of 632) with videos related to

Sort By:
Pageof 64
Journal of Hepatology|July 23, 2008
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infectionJuliane Halangk, Christoph Sarrazin, Konrad Neumann, et al.
Journal of Virology|March 29, 2013
Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patientsJulia Dietz, Sven-Eric Schelhorn, Daniel Fitting, et al.
Journal of Hepatology|April 2, 2017
Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral loadSandra Westhaus, Maximilian Deest, Anna T X Nguyen, et al.
Journal of Hepatology|May 21, 2008
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infectionAndrej Potthoff, Heiner Wedemeyer, Wulf O Boecher, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 23, 2019
The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieuHans Dieter Nischalke, Philipp Lutz, Eva Bartok, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2020
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort studyPietro Lampertico, Thomas Berg, Maria Buti, et al.
Cancers|October 14, 2022
Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular CarcinomasAnne Olbrich, Olga Gros, Sebastian Ebel, et al.
Antimicrobial Agents and Chemotherapy|April 9, 2014
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patientsDouglas Dieterich, Tarik Asselah, Dominique Guyader, et al.
Purinergic Signalling|September 24, 2018
Mononuclear-cell-derived microparticles attenuate endothelial inflammation by transfer of miR-142-3p in a CD39 dependent mannerStephanie Kuhn, Katrin Splith, Cindy Ballschuh, et al.
JHEP Reports : Innovation in Hepatology|September 25, 2023
HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriersLuisa Roade, Mar Riveiro-Barciela, Maria Pfefferkorn, et al.
Pageof 64